Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: A systematic review of the literature

International Journal of Clinical Practice

Volumn 65, Issue 5, 2011, Pages 567-585

  Sexton, C C ^a   Notte, S M ^a   Maroulis, C ^b   Dmochowski, R R ^c   Cardozo, L ^d   Subramanian, D ^b   Coyne, K S ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ETHICON INC   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; DOXAZOSIN; FESOTERODINE; FLAVOXATE; IMIDAFENACIN; OXYBUTYNIN; PLACEBO; PROPIVERINE; SOLIFENACIN; TAMSULOSIN; TOLTERODINE; TROSPIUM CHLORIDE;

BEHAVIOR THERAPY; BLADDER DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; ILLNESS BEHAVIOR; MAJOR CLINICAL STUDY; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CHOLINERGIC ANTAGONISTS; COST OF ILLNESS; DOUBLE-BLIND METHOD; HUMANS; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER, OVERACTIVE;

EID: 79954490139     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02626.x     Document Type: Review

References (174)

1. Abrams P, Artibani W, Cardozo L, et al., Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009; 28: 287.
2. Haylen BT, de Ridder D, Freeman RM, et al., An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 4-20.
3. Benner JS, Becker R, Fanning K, et al., Bother related to bladder control and health care seeking behavior in adults in the United States. J Urol 2009; 181: 2591-8.
4. Coyne KS, Sexton CC, Irwin DE, et al., The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 1388-95. (Pubitemid 351623990)
5. Dmochowski RR, Newman DK,. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin 2007; 23: 65-76. (Pubitemid 46191671)
6. Irwin DE, Milsom I, Kopp Z, Abrams P,. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 2008; 53: 1029-37.
7. Kannan H, Radican L, Turpin RS, Bolge SC,. Burden of illness associated with lower urinary tract symptoms including overactive bladder/urinary incontinence. Urology 2009; 74: 34-8.
8. Sexton CC, Coyne KS, Vats V, et al., Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care 2009; 15 (4 Suppl.): S98-107.
9. Choo MS, Ku JH, Lee JB, et al., Cross-cultural differences for adapting overactive bladder symptoms: results of an epidemiologic survey in Korea. World J Urol 2007; 25: 505-11.
10. Corcos J, Schick E,. Prevalence of overactive bladder and incontinence in Canada. Can J Urol 2004; 11: 2278-84.
11. Coyne KS, Sexton CC, Vats V, et al., National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2010. In press.
12. Tikkinen KAO, Tammela TLJ, Rissanen AM, et al., Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS ONE 2007; 195: 1-8.
13. Herschorn S, Gajewski J, Schulz J, Corcos J,. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU Int 2008; 101: 52-8. (Pubitemid 350233562)
14. Irwin DE, Milsom I, Hunskaar S, et al., Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14. discussion 14-5.
15. Milsom I, Abrams P, Cardozo L, et al., How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6. (Pubitemid 34204313)
16. Milsom I, Irwin DE,. A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: results from the EPIC Study. Eur Urol 2007; (Suppl. 6): 4-9. (Pubitemid 44821939)
17. Stewart WF, Van Rooyen JB, Cundiff GW, et al., Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36. (Pubitemid 44175300)
18. Ioannidis JP,. Why most published research findings are false. PLoS Med 2005; 2: e124.
19. Schabert VF, Bavendam T, Goldberg EL, et al., Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care 2009; 15 (4 Suppl.): S118-22.
20. Burgio KL, Kraus SR, Menefee S, et al., Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 2008; 149: 161-9.
21. Burgio KL, Locher JL, Goode PS, et al., Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998; 280: 1995-2000.
22. Burgio KL, Locher JL, Goode PS,. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48: 370-4. (Pubitemid 30207759)
23. Epstein BJ, Gums JG, Molina E,. Newer agents for the management of overactive bladder. Am Fam Physician 2006; 74: 2061-8. (Pubitemid 44927019)
24. Wagg AS, Cardozo L, Chapple C, et al., Overactive bladder syndrome in older people. BJU Int 2007; 99: 502-9. (Pubitemid 46238818)
25. D'Souza AO, Smith MJ, Miller LA, et al., Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008; 14: 291-301. (Pubitemid 351711980)
26. Noe L, Becker R, Williamson T, Chen D,. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm 2002; 8: 343-52.
27. Sand PK, Miklos J, Ritter H, Appell R,. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15: 243-8. (Pubitemid 39149294)
28. Caetano PA, Lam JM, Morgan SG,. Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization. Clin Ther 2006; 28: 1411-24; discussion 0. (Pubitemid 44585292)
29. Cramer J, Rosenheck R, Kirk G, et al., Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003; 6: 566-73. (Pubitemid 37187719)
30. Lutfey KE, Wishner WJ,. Beyond "compliance" is "adherence". Improving the prospect of diabetes care. Diabetes Care 1999; 22: 635-9. (Pubitemid 29153053)
31. Pelletier EM, Vats V, Clemens JQ,. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Am J Manag Care 2009; 15 (4 Suppl.): S108-14.
32. Yu YF, Nichol MB, Yu AP, Ahn J,. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 2005; 8: 495-505. (Pubitemid 41726103)
33. Abrams P, Cardozo L, Chapple C, et al., Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006; 13: 692-8. (Pubitemid 43926756)
34. Abrams P, Freeman R, Anderstrom C, Mattiasson A,. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-10. (Pubitemid 28300606)
35. Abrams P, Kaplan S, De Koning Gans HJ, Millard R,. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999-1004. discussion. (Pubitemid 43200054)
36. Abrams P, Malone-Lee J, Jacquetin B, et al., Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001; 18: 551-60. (Pubitemid 32664728)
37. Anderson RU, MacDiarmid S, Kell S, et al., Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 502-11. (Pubitemid 44138258)
38. Anderson RU, Mobley D, Blank B, et al., Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999; 161: 1809-12. (Pubitemid 29420737)
39. Appell RA, Sand P, Dmochowski R, et al., Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76: 358-63. (Pubitemid 32248750)
40. Appell RA, Abrams P, Drutz HP, et al., Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001; 19: 141-7. (Pubitemid 33777045)
41. Armstrong RB, Luber KM, Peters KM,. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. Int Urol Nephrol 2005; 37: 247-52. (Pubitemid 41349185)
42. Barkin J, Corcos J, Radomski S, et al., A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004; 26: 1026-36. (Pubitemid 39141805)
43. Bemelmans BL, Kiemeney LA, Debruyne FM,. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol 2000; 37: 709-13. (Pubitemid 30255789)
44. Birns J, Lukkari E, Malone-Lee JG,. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 2000; 85: 793-8. (Pubitemid 30242779)
45. Boone TB, Kusek JW, Nyberg LM, et al., Treatment patterns and associated symptom improvement during six months of care for overactive bladder: a prospective, observational study. Clin Ther 2002; 24: 397-408. (Pubitemid 34275861)
46. Burgio KL, Locher JL, Roth DL, Goode PS,. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. J Gerontol B Psychol Sci Soc Sci 2001; 56: P46-51. (Pubitemid 32047341)
47. Cardozo L, Castro-Diaz D, Gittelman M, et al., Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 512-9. (Pubitemid 44138259)
48. Cardozo L, Coyne KS, Versi E,. Validation of the urgency perception scale. BJU Int 2005; 95: 591-6. (Pubitemid 40311479)
49. Cardozo L, Hessdorfer E, Milani R, et al., Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102: 1120-7.
50. Cardozo L, Lisec M, Millard R, et al., Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-24. (Pubitemid 39363090)
51. Chancellor MB, Freedman S, Mitcheson HD, et al., Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000; 19: 83-91. (Pubitemid 30139292)
52. Chancellor MB, Zinner N, Whitmore K, et al., Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008; 30: 1766-81.
53. Chapple C, DuBeau C, Ebinger U, et al., Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007; 23: 2347-58. (Pubitemid 350033436)
54. Chapple C, Van Kerrebroeck P, Tubaro A, et al., Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12. (Pubitemid 47332062)
55. Chapple CR, Fianu-Jonsson A, Indig M, et al., Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007; 52: 1195-203. (Pubitemid 47337035)
56. Chapple CR, Martinez-Garcia R, Selvaggi L, et al., A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-70. (Pubitemid 41188406)
57. Chapple CR, Rechberger T, Al-Shukri S, et al., Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10. (Pubitemid 38253574)
58. Chapple CR, Van Kerrebroeck PE, Junemann KP, et al., Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008; 102: 1128-32.
59. Choo MS, Doo CK, Lee KS,. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). Int J Clin Pract 2008; 62: 191-6.
60. Choo MS, Lee JZ, Lee JB, et al., Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. Int J Clin Pract 2008; 62: 1675-83.
61. Chu FM, Dmochowski RR, Lama DJ, et al., Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol 2005; 192: 1849-54. discussion 54-5.
62. Diokno A, Sand P, Labasky R, et al., Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002; 34: 43-9. (Pubitemid 36090223)
63. Diokno AC, Appell RA, Sand PK, et al., Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95. (Pubitemid 36665898)
64. Dmochowski RR, Sand PK, Zinner NR, Staskin DR,. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008; 71: 449-54. (Pubitemid 351374733)
65. Drutz HP, Appell RA, Gleason D, et al., Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 283-9. (Pubitemid 29465392)
66. Dwyer P, Kelleher C, Young J, et al., Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourol Urodyn 2008; 27: 540-7.
67. Elinoff V, Bavendam T, Glasser DB, et al., Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006; 60: 745-51. (Pubitemid 43811659)
68. Foote J, Glavind K, Kralidis G, Wyndaele JJ,. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005; 48: 471-7. (Pubitemid 41188407)
69. Freeman R, Hill S, Millard R, et al., Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003; 102: 605-11. (Pubitemid 37311230)
70. Garely AD, Kaufman JM, Sand PK, et al., Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006; 28: 1935-46. (Pubitemid 46043507)
71. Giannitsas K, Perimenis P, Athanasopoulos A, et al., Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur Urol 2004; 46: 776-82. discussion 82-3. (Pubitemid 39488412)
72. Goode PS, Burgio KL, Locher JL, et al., Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc 2002; 50: 808-16. (Pubitemid 34496675)
73. Haab F, Cardozo L, Chapple C, Ridder AM,. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-84. (Pubitemid 40248865)
74. Haab F, Corcos J, Siami P, et al., Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006; 98: 1025-32. (Pubitemid 44536453)
75. Halaska M, Ralph G, Wiedemann A, et al., Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20: 392-9. (Pubitemid 44175311)
76. Herschorn S, Heesakkers J, Castro-Diaz D, et al., Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 2008; 24: 3513-21.
77. Hill S, Elhilali M, Millard RJ, et al., Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin 2007; 23: 2697-704. (Pubitemid 350146407)
78. Hill S, Khullar V, Wyndaele JJ, Lheritier K,. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 239-47.
79. Homma Y, Paick JS, Lee JG, Kawabe K,. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003; 92: 741-7. (Pubitemid 37475818)
80. Homma Y, Yamaguchi O,. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008; 15: 986-91.
81. Homma Y, Yamaguchi O,. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009; 16: 499-506.
82. Jacquetin B, Wyndaele J,. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 2001; 98: 97-102. (Pubitemid 32758842)
83. Junemann KP, Halaska M, Rittstein T, et al., Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 2005; 48: 478-82. (Pubitemid 41188408)
84. Kafri R, Langer R, Dvir Z, Katz-Leurer M,. Rehabilitation vs drug therapy for urge urinary incontinence: short-term outcome. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 407-11. (Pubitemid 46390134)
85. Kafri R, Shames J, Raz M, Katz-Leurer M,. Rehabilitation versus drug therapy for urge urinary incontinence: long-term outcomes. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 47-52. (Pubitemid 350193854)
86. Kaplan SA, Roehrborn CG, Chancellor M, et al., Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008; 102: 1133-9.
87. Karram MM, Toglia MR, Serels SR, et al., Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009; 73: 14-8.
88. Kay G, Crook T, Rekeda L, et al., Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317-26. (Pubitemid 44038078)
89. Kelleher CJ, Cardozo L, Chapple CR, et al., Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95: 81-5. (Pubitemid 350020875)
90. Kelleher CJ, Kreder KJ, Pleil AM, et al., Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8 (19 Suppl.): S616-30. (Pubitemid 36050143)
91. Kelleher CJ, Reese PR, Pleil AM, Okano GJ,. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8 (19 Suppl.): S608-15. (Pubitemid 36050142)
92. Kelleher CJ, Tubaro A, Wang JT, Kopp Z,. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008; 102: 56-61. (Pubitemid 351799457)
93. Khullar V, Rovner ES, Dmochowski R, et al., Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008; 71: 839-43.
94. Klutke CG, Burgio KL, Wyman JF, et al., Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol 2009; 181: 2599-607.
95. Kreder K, Mayne C, Jonas U,. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002; 41: 588-95. (Pubitemid 35333914)
96. Kumar A,. Efficacy and safety of tolterodine in subjects with symptoms of overactive bladder: an open label, noncomparative, prospective, multicentric study. Indian J Urol 2002; 19: 73-8. (Pubitemid 36347898)
97. Lackner TE, Wyman JF, McCarthy TC, et al., Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008; 56: 862-70. (Pubitemid 351652413)
98. Lauti M, Herbison P, Hay-Smith J, et al., Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 1533-43.
99. Lee JY, Kim HW, Lee SJ, et al., Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-20. (Pubitemid 39472476)
100. Leung HY, Yip SK, Cheon C, et al., A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 2002; 90: 375-80. (Pubitemid 36124767)
101. Lipton RB, Kolodner K, Wesnes K,. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173: 493-8.
102. MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski RR,. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol 2005; 174: 1301-5. discussion 5. (Pubitemid 41318712)
103. MacDiarmid SA, Peters KM, Chen A, et al., Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008; 83: 1002-10.
104. Madersbacher H, Halaska M, Voigt R, et al., A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999; 84: 646-51. (Pubitemid 29457181)
105. Malone-Lee J, Shaffu B, Anand C, Powell C,. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001; 165: 1452-6. (Pubitemid 32410212)
106. Malone-Lee JG, Al-Buheissi S,. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009; 103: 931-7.
107. Malone-Lee JG, Walsh JB, Maugourd MF,. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49: 700-5. (Pubitemid 32652460)
108. Metello J, Nogueira B, Torgal M, et al., Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 1021-5. (Pubitemid 350130405)
109. Michel MC, de la Rosette JJ, Piro M, Schneider T,. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol 2005; 48: 110-5. (Pubitemid 40835603)
110. Michel MC, Schneider T, Krege S, Goepel M,. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002; 168: 1027-31.
111. Michel MC, Wetterauer U, Vogel M, de la Rosette JJ,. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf 2008; 31: 505-14. (Pubitemid 351693683)
112. Millard R, Tuttle J, Moore K, et al., Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 1551-5. (Pubitemid 29420817)
113. Millard RJ, Halaska M,. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 2006; 22: 41-8. (Pubitemid 43106906)
114. Nitti VW, Dmochowski R, Sand PK, et al., Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178: 2488-94. (Pubitemid 350052177)
115. Pizzi LT, Talati A, Gemmen E, et al., Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics 2009; 27: 329-39.
116. Rackley R, Weiss JP, Rovner ES, et al., Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006; 67: 731-6. discussion 6.
117. Roberts R, Bavendam T, Glasser DB, et al., Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract 2006; 60: 752-8. (Pubitemid 43811660)
118. Roehrborn CG, Abrams P, Rovner ES, et al., Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 2006; 97: 1003-6.
119. Roehrborn CG, Kaplan SA, Jones JS, et al., Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009; 55: 472-9.
120. Rogers R, Bachmann G, Jumadilova Z, et al., Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 1551-7.
121. Rogers RG, Omotosho T, Bachmann G, et al., Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 381-5.
122. Salvatore S, Khullar V, Cardozo L, et al., Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol 2005; 119: 237-41. (Pubitemid 40460389)
123. Salvatore S, Serati M, Digesu GA, et al., Efficacy of tolterodine in relation to different urodynamic findings of detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 701-4. (Pubitemid 351516948)
124. Sand P, Zinner N, Newman D, et al., Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007; 99: 836-44. (Pubitemid 46439555)
125. Sand PK, Morrow JD, Bavendam T, et al., Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 827-35.
126. Sand PK, Steers WD, Dmochowski R, et al., Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 667-75.
127. Siami P, Seidman LS, Lama D,. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002; 24: 616-28. (Pubitemid 34492883)
128. Staskin D, Sand P, Zinner N, Dmochowski R,. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007; 178: 978-83. discussion 83-4.
129. Staskin DR, Dmochowski RR, Sand PK, et al., Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009; 181: 1764-72.
130. Steers W, Corcos J, Foote J, Kralidis G,. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005; 95: 580-6. (Pubitemid 40311477)
131. Sussman D, Garely A,. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002; 18: 177-84.
132. Swift S, Garely A, Dimpfl T, Payne C,. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14: 50-4. discussion 4-5.
133. Swift SE, Siami P, Forero-Schwanhaeuser S,. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: an open-label, flexible-dosing, multicentre study. Clin Drug Investig 2009; 29: 305-16.
134. Takei M, Homma Y,. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol 2005; 12: 456-64. (Pubitemid 41015153)
135. Ulshofer B, Bihr AM, Bodeker RH, et al., Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clin Drug Invest 2001; 21: 563-9. (Pubitemid 32783716)
136. Van Kerrebroeck P, Kreder K, Jonas U, et al., Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 414-21. (Pubitemid 32192963)
137. Versi E, Appell R, Mobley D, et al., Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000; 95: 718-21. (Pubitemid 30210058)
138. Wagg A, Wyndaele JJ, Sieber P,. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006; 4: 14-24.
139. Wang AC, Chih SY, Chen MC,. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Urology 2006; 68: 999-1004. (Pubitemid 44750132)
140. Wyndaele JJ, Goldfischer ER, Morrow JD, et al., Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 2009; 63: 560-7.
141. Yamaguchi O, Nishizawa O, Takeda M, et al., Clinical guidelines for overactive bladder. Int J Urol 2009; 16: 126-42.
142. Zinner N, Gittelman M, Harris R, et al., Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-5. quiz 435. (Pubitemid 38625460)
143. Zinner N, Kobashi KC, Ebinger U, et al., Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract 2008; 62: 1664-74.
144. Zinner N, Noe L, Rasouliyan L, et al., Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin 2008; 24: 1583-91. (Pubitemid 351929057)
145. Zinner N, Susset J, Gittelman M, et al., Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 2006; 60: 119-26. (Pubitemid 43732588)
146. Zinner N, Tuttle J, Marks L,. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005; 23: 248-52.
147. Zinner NR, Mattiasson A, Stanton SL,. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799-807. (Pubitemid 34496674)
148. Rudy D, Cline K, Harris R, et al., Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006; 97: 540-6.
149. Rudy D, Cline K, Harris R, et al., Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006; 67: 275-80. (Pubitemid 43189841)
150. Garely AD, Lucente V, Vapnek J, Smith N,. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Ann Pharmacother 2007; 41: 391-8.
151. Dmochowski RR, Davila GW, Zinner NR, et al., Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580-6. (Pubitemid 34793301)
152. Nitti VW, Dmochowski R, Appell RA, et al., Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int 2006; 97: 1262-6. (Pubitemid 43907334)
153. Kaplan SA, Roehrborn CG, Dmochowski R, et al., Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006; 68: 328-32. (Pubitemid 44175507)
154. Kaplan SA, Roehrborn CG, Rovner ES, et al., Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296: 2319-28. (Pubitemid 44749359)
155. Homma Y, Kawabe K,. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004; 22: 251-6. (Pubitemid 41406544)
156. Corcos J, Casey R, Patrick A, et al., A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 2006; 97: 520-7.
157. Echols K, Verma U, Policaro F, Medina CA,. Idiopathic bladder hyperactivity and ditropan: an efficacy and compliance issue. Obstet Gynecol 2000; 95: S1-24.
158. Balkrishnan R, Bhosle MJ, Camacho FT, Anderson RT,. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol 2006; 175: 1067-71. discussion 71-2. (Pubitemid 43200091)
159. Desgagne A, LeLorier J,. Incontinence drug utilization patterns in Quebec, Canada. Value Health 1999; 2: 452-8.
160. Gopal M, Haynes K, Bellamy SL, Arya LA,. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008; 112: 1311-8.
161. Hughes DA, Dubois D,. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 2004; 22: 1047-59. (Pubitemid 39612039)
162. Lawrence M, Guay DR, Benson SR, Anderson MJ,. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000; 20: 470-5. (Pubitemid 30198852)
163. Malone DC, Okano GJ,. Treatment of urge incontinence in Veterans Affairs medical centers. Clin Ther 1999; 21: 867-77. (Pubitemid 29291444)
164. Odeyemi IA, Dakin HA, O'Donnell RA, et al., Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract 2006; 60: 949-58. (Pubitemid 44082286)
165. Perfetto EM, Subedi P, Jumadilova Z,. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. Am J Manag Care 2005; 11 (4 Suppl.): S150-7. (Pubitemid 41022723)
166. Shaya FT, Blume S, Gu A, et al., Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005; 11 (4 Suppl.): S121-9. (Pubitemid 41022720)
167. Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA,. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care 2005; 11 (4 Suppl.): S140-9. (Pubitemid 41022722)
168. Getsios D, Caro JJ, Ishak KJ, et al., Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin Ther 2004; 26: 431-8. (Pubitemid 38457336)
169. Ko Y, Malone DC, Armstrong EP,. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006; 26: 1694-702. (Pubitemid 44885326)
170. Speakman M, Khullar V, Mundy A, et al., A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008; 24: 2173-9.
171. Yeaw J, Benner JS, Walt JG, et al., Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009; 15: 728-40.
172. Cramer JA, Bradley-Kennedy C, Scalera A,. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J 2007; 14: 25-9. (Pubitemid 46637657)
173. Staskin DR, Te AE,. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int 2006; 97: 1256-61. (Pubitemid 43907333)
174. Herschorn S, Becker D, Miller E, et al., Impact of a health education intervention in overactive bladder patients. Can J Urol 2004; 11: 2430-7.